{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Multicenter, Randomized, Double-Blind, Phase 2\/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-multicenter-randomized-double-blind-phase-2-3-study-of-bca101-or-placebo-in-combination-with-pembrolizumab-for-first-line-treatment-of-pd-l1-positive-recurrent-metastatic-head-and-neck-squamous\/#breadcrumbitem"}]}